We are live on ! Find out more
PBAXU

Phoenix Biotech Acquisition Corp. Unit
PBAXU

Delisted

PBAXU was delisted on the 7th of February, 2024.

Back to rankings

3 hedge funds and large institutions have $8.43K invested in Phoenix Biotech Acquisition Corp. Unit in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

49% more capital invested

Capital invested by funds: $5.64K → $8.43K (+$2.79K)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

PBAXU Hedge Fund Activity: Q4 2023 in Review

3 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q4 2023, worth a combined $8.43K — up 49% from $5.64K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PBAXU positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

  • 3 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q4 2023, up from 2 in Q3 2023.
  • Funds reported $8.43K of Phoenix Biotech Acquisition Corp. Unit stock for Q4 2023, up 49% quarter-over-quarter.
  • 1 fund opened new Phoenix Biotech Acquisition Corp. Unit positions in Q4 2023 and 0 closed out, a net change of +1 holder.

Based on aggregated 13F filings for Q4 2023.